Denise Neves Gameiro, Author at Labiotech.eu - Page 10 of 24

About

Journalist intern. Studied Bioengineering in Porto and was a lab rat in Sweden. Enjoying Berlin and the company of Labiotech’s resident plants.

Articles by Denise Neves Gameiro

bioart julia lohmann maggots microbiome algae

News and Trends 25 Jun 2016

How to do art with 9000 Petri Dishes? Julia Lohmann’s BioArt

Julia Lohmann grew up in the German countryside, studied design in England and worked on a farm in Iceland. Now as a designer and researcher, she brings all these experiences to her work – with maggots, bacteria, algae and 9000 petri dishes. Julia Lohmann started with sculpture by collecting driftwood during her childhood in Hildesheim, in […]

June 25, 2016 - 2 minutesmins - By Denise Neves Gameiro

red algae global warming bioalbedo gfz potsdam

News and Trends 24 Jun 2016

Why would Snow-growing Algae be killing Glaciers?

Red Algae bloom on glaciers during summer, which may give the snow more than a nice pink shade. The darker color makes the glacier melt faster – a previously overlooked mechanism in climate change. In biotech, algae almost became synonymous with unlimited potential, including as a promising new generation of biofuels – so they should be pretty environment-friendly, right? […]

June 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

axon neuroscience alzheimer vaccine tau

News and Trends 23 Jun 2016

Alzheimer’s closer to a Vaccine with new Slovakian Phase II Trial

Axon Neuroscience is starting a Phase II trial with its immunotherapy for Alzheimer’s disease, which redirects the immune system against defective Tau proteins, thought to be the main cause of this major disease. Alzheimer’s disease is the cause of up to 70% of dementia cases, according to WHO, which translates in over 30 million patients […]

June 23, 2016 - 2 minutesmins - By Denise Neves Gameiro

venomab recombinant antivenom laustsen refresh

News and Trends 23 Jun 2016

‘Snake-bite Jesus’ pitched at Labiotech Refresh

VenomAb made quite an impression at the Startup Battle of Labiotech Refresh. Want to know what makes a biotech audience gasp unanimously? Then take a look at VenomAb’s pitch… We had Andreas Laustsen, founder of VenomAb, pitch his startup’s mission to bring antivenoms out of the 1900s into the modern age of biotech. The idea really captured […]

June 23, 2016 - 3 minutesmins - By Denise Neves Gameiro

median microsoft big data oncology

News and Trends 22 Jun 2016

What is Microsoft doing with this French Precision Medicine Biotech?

Median Technologies is partnering up with software giant Microsoft to integrate big data into its oncology imaging systems – and deliver Precision Medicine from the cloud. Medical imaging is an important part of the rise of digital medicine. Cool projects in the field include the aortic graft simulation of EVARplanning (one of the startups at Italian incubator […]

June 22, 2016 - 2 minutesmins - By Denise Neves Gameiro

crispr cas9 clinical trial t cell therapy

News and Trends 22 Jun 2016

World’s first CRISPR Clinical trial has just been Approved!

CRISPR has received a regulatory green light in what could be the first clinical trial with the “scientific discovery of the century”. It’ll be used to improve cancer cell therapies. CRISPR has already revolutionized biotech, quickly overtaking the field of gene editing. It also has immense potential in the therapeutic field, so it’s not surprising there’s a lot […]

June 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

f2g fungal infections antifungals aspergillosis

News and Trends 22 Jun 2016

Massive Round: Novel Antifungals get €53M from Top-Notch Investors

F2G has raised €53M to advance its news class of treatments for life-threatening fungal infections, including invasive aspergillosis. The technology has attracted some of the major biotech investors in Europe. Based in Manchester (UK), F2G focuses on developing therapies for invasive fungal infections such as aspergillosis. This type of infections mostly affect patients that are […]

June 22, 2016 - 2 minutesmins - By Denise Neves Gameiro

circassia cat grass allergy toleromune spire

News and Trends 21 Jun 2016

Allergy Immunotherapy Knocked Out in Phase III by an ‘Overperforming Placebo’

Circassia’s pipeline takes a major step back as its therapy for cat allergy gets disappointing results — it had the same effect as the placebo. Stocks promptly sank by 65%. The Oxford-based Circassia has been a major European player in the field of allergy immunotherapies. It made a splash when it raised €267.7M in the London Stock […]

June 21, 2016 - 3 minutesmins - By Denise Neves Gameiro

labiotech refresh microbiome isabelle cremoux

News and Trends 21 Jun 2016

“The Microbiome will be as big as Biotech in 10 Years”

Isabelle de Cremoux, the CEO of Seventure Partners, was at Labiotech Refresh to tell us when and how she fell in love with the microbiome and what the future holds for this exciting field. De Cremoux is the person behind Seventure, one of the top European VCs and the first in the world to focus mainly […]

June 21, 2016 - 4 minutesmins - By Denise Neves Gameiro

astrazeneca asthma copd epigenetic targets

News and Trends 21 Jun 2016

UK Partnership is looking for new Epigenetic targets in Respiratory Disease

AstraZeneca and MRC Technology are launching an initiative to find new epigenetic targets in respiratory disease. By picking promising academic research, the two parties expect to lock in new drugs for diseases like asthma. After partnering up with genomics elite for a new biobank, AstraZeneca is again preparing to tap into collaborations with academia. This […]

June 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

gmo tobacco artemisinin malaria synbio

News and Trends 20 Jun 2016

GMO Tobacco could Produce cheaper Medicine for Malaria

Researchers from the Max Planck Institute of Molecular Plant Physiology in Potsdam have altered tobacco to produce large yields of artemisinin – the most effective treatment for malaria but still without a cheap and reliable source. Artemisinin is used in the most effective treatments against malaria, the discovery of which was worth a Nobel Prize. […]

June 20, 2016 - 3 minutesmins - By Denise Neves Gameiro

curetis blood infection diagnostic pathogen resistance

News and Trends 20 Jun 2016

This Sepsis Detection Test saves 24h for Faster Treatment

Curetis has received great results for its diagnostic kit. This new technology to detect sepsis is delivering the same results as standard tests, but it’s faster by 24 hours – critical time to deal with life-threatening infections. Based in Stuttgart (Germany), Curetis was the only German biotech to do an IPO in 2015. It did so with a bang, […]

June 20, 2016 - 2 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT